JP2016517402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517402A5 JP2016517402A5 JP2015562395A JP2015562395A JP2016517402A5 JP 2016517402 A5 JP2016517402 A5 JP 2016517402A5 JP 2015562395 A JP2015562395 A JP 2015562395A JP 2015562395 A JP2015562395 A JP 2015562395A JP 2016517402 A5 JP2016517402 A5 JP 2016517402A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant
- growth factor
- protein according
- synthetic protein
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003102 growth factor Substances 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 15
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000006386 neutralization reaction Methods 0.000 claims 5
- 125000006850 spacer group Chemical group 0.000 claims 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 3
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 3
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 3
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940031348 multivalent vaccine Drugs 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791268P | 2013-03-15 | 2013-03-15 | |
| US61/791,268 | 2013-03-15 | ||
| PCT/IB2014/001125 WO2014140894A2 (en) | 2013-03-15 | 2014-03-17 | Self-assembling synthetic proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517402A JP2016517402A (ja) | 2016-06-16 |
| JP2016517402A5 true JP2016517402A5 (enExample) | 2017-03-23 |
| JP6873530B2 JP6873530B2 (ja) | 2021-05-19 |
Family
ID=51225849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562395A Expired - Fee Related JP6873530B2 (ja) | 2013-03-15 | 2014-03-17 | 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ） |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10736948B2 (enExample) |
| EP (1) | EP2970409A2 (enExample) |
| JP (1) | JP6873530B2 (enExample) |
| KR (2) | KR102391734B1 (enExample) |
| CN (2) | CN105209481B (enExample) |
| AU (1) | AU2014229561B2 (enExample) |
| BR (1) | BR112015023402A2 (enExample) |
| CA (1) | CA2904506A1 (enExample) |
| HK (1) | HK1214606A1 (enExample) |
| IL (3) | IL286537B (enExample) |
| MX (2) | MX385451B (enExample) |
| MY (1) | MY187936A (enExample) |
| RU (1) | RU2747857C2 (enExample) |
| WO (1) | WO2014140894A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12595297B2 (en) | 2015-05-12 | 2026-04-07 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| CA3070034A1 (en) * | 2017-07-18 | 2019-01-24 | In3Bio Ltd. | Synthetic proteins and therapeutic uses thereof |
| EP3986447A4 (en) * | 2019-06-18 | 2023-08-16 | Citranvi Biosciences, LLC | RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES |
| CN120904351A (zh) * | 2019-06-25 | 2025-11-07 | 因斯瑞拜奥有限公司 | 稳定的嵌合合成蛋白及其治疗用途 |
| KR20220099990A (ko) | 2019-11-07 | 2022-07-14 | 인3바이오 리미티드 | 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물 |
| CN114019166B (zh) * | 2021-09-27 | 2024-02-27 | 浙江省食品药品检验研究院 | 一种检测龙葵素的试纸条及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US6153203A (en) | 1993-10-08 | 2000-11-28 | Duotol Ab | Immunological tolerance-inducing agent |
| EP0657175B1 (en) * | 1993-12-09 | 2005-03-02 | Centro de Inmunologia Molecular | Vaccine comprising human autologous epidermal growth factor and use thereof |
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| CA2745736C (en) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
| AU734180B2 (en) | 1997-08-29 | 2001-06-07 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
| DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001027144A2 (en) | 1999-10-08 | 2001-04-19 | Active Biotech Ab | Ab5 toxin b subunit mutants with altered chemical conjugation characteristics |
| PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
| DE60232603D1 (de) | 2001-06-21 | 2009-07-23 | Teijin Ltd | Nahinfrarot-schutzfolie |
| GB0115382D0 (en) | 2001-06-22 | 2001-08-15 | Univ Bristol | Mutant |
| EP1490481A4 (en) | 2001-12-14 | 2005-12-07 | Centocor Inc | CLONAL CELL LINES OF MYELOMES FOR PRODUCING PROTEINS IN A CHEMICALLY DEFINED ENVIRONMENT |
| US8206965B2 (en) * | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| JP4623625B2 (ja) | 2003-07-24 | 2011-02-02 | 株式会社AMBiS | ヘテロ型５量体組換えワクチン |
| US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| KR20070004560A (ko) * | 2003-12-05 | 2007-01-09 | 노오쓰웨스턴 유니버시티 | 성장 인자 전달을 위한 자가조립 펩티드 친양매성 화합물들및 관련 방법들 |
| ATE555127T1 (de) | 2004-02-11 | 2012-05-15 | Angeletti P Ist Richerche Bio | Fusionsproteine des karzinomembryonalen antigens und deren verwendungen |
| EP1921149A1 (en) * | 2006-11-13 | 2008-05-14 | AEterna Zentaris GmbH | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
| US7946815B2 (en) | 2007-03-27 | 2011-05-24 | Siemens Energy, Inc. | Airfoil for a gas turbine engine |
| CN101970498A (zh) | 2007-10-25 | 2011-02-09 | 维文蒂阿生物技术公司 | 针对变体HnRNPG的癌相关表位的抗体及其应用 |
| CN101945666A (zh) | 2007-12-19 | 2011-01-12 | Mivac发展股份公司 | 治疗自身免疫和过敏性疾病的组合物及方法 |
| EP2288380B1 (en) | 2008-06-09 | 2020-06-03 | Bharat Biotech International Limited | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same |
| JP2010050586A (ja) | 2008-08-20 | 2010-03-04 | Nec Corp | 通信装置及びそれに用いる装置コンポーネント複合冗長化方法 |
| US20120088819A1 (en) * | 2008-10-31 | 2012-04-12 | Makoto Inoue | Method for enhancing expression of recombinant protein |
| JP5734201B2 (ja) * | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| JP2011097930A (ja) * | 2009-10-07 | 2011-05-19 | Hokkaido Univ | 光活性化生理機能センサータンパク質 |
| RU2480524C2 (ru) * | 2010-09-13 | 2013-04-27 | Учреждение Российской академии наук Институт биоорганической химии им. академии М.М. Шемякина и Ю.А. Овчинникова РАН | Конструкция на основе белковой пары барназа-барстар и способ ее получения |
| AU2012222833B2 (en) * | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| CN102604993B (zh) | 2012-01-10 | 2013-03-20 | 天津耀宇生物技术有限公司 | 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法 |
-
2014
- 2014-03-17 WO PCT/IB2014/001125 patent/WO2014140894A2/en not_active Ceased
- 2014-03-17 MY MYPI2015703117A patent/MY187936A/en unknown
- 2014-03-17 RU RU2015143217A patent/RU2747857C2/ru not_active Application Discontinuation
- 2014-03-17 HK HK16102480.5A patent/HK1214606A1/zh unknown
- 2014-03-17 MX MX2015012461A patent/MX385451B/es unknown
- 2014-03-17 EP EP14744148.9A patent/EP2970409A2/en active Pending
- 2014-03-17 KR KR1020157026975A patent/KR102391734B1/ko active Active
- 2014-03-17 CN CN201480026671.3A patent/CN105209481B/zh active Active
- 2014-03-17 CN CN202010734323.9A patent/CN111978409B/zh active Active
- 2014-03-17 BR BR112015023402A patent/BR112015023402A2/pt not_active Application Discontinuation
- 2014-03-17 JP JP2015562395A patent/JP6873530B2/ja not_active Expired - Fee Related
- 2014-03-17 KR KR1020207037800A patent/KR102427429B1/ko active Active
- 2014-03-17 AU AU2014229561A patent/AU2014229561B2/en active Active
- 2014-03-17 CA CA2904506A patent/CA2904506A1/en active Pending
- 2014-03-17 IL IL286537A patent/IL286537B/en unknown
-
2015
- 2015-09-03 IL IL241116A patent/IL241116B/en active IP Right Grant
- 2015-09-11 MX MX2021010021A patent/MX2021010021A/es unknown
- 2015-09-15 US US14/854,224 patent/US10736948B2/en active Active
-
2020
- 2020-03-04 IL IL273051A patent/IL273051B/en unknown
- 2020-04-08 US US16/843,118 patent/US11419923B2/en active Active
-
2022
- 2022-07-12 US US17/862,952 patent/US12433939B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201282T1 (hr) | Rekombinantni proteini i njihove terapeutske upotrebe | |
| van Riet et al. | Mucosal IgA responses in influenza virus infections; thoughts for vaccine design | |
| CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
| RU2015143217A (ru) | Самособирающиеся синтетические белки | |
| Kim et al. | Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection | |
| HRP20100228T1 (hr) | Modificirani hekson protein adenovirusa i njegove uporabe | |
| JP2015096070A5 (enExample) | ||
| JP2014510519A5 (enExample) | ||
| HRP20251060T1 (hr) | Samosklapajuće proteinske nanostrukture koje prikazuju f proteine paramiksovirusa i/ili pneumovirusa i njihova uporaba | |
| JP2017029157A5 (enExample) | ||
| JP2018148890A5 (enExample) | ||
| JP2014530010A5 (enExample) | ||
| JP2016199557A5 (enExample) | ||
| JP2017511140A5 (enExample) | ||
| JP2018501801A (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2010519931A5 (enExample) | ||
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| MX380631B (es) | Vectores de adenovirus canino | |
| JP2015529678A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| EA201691611A1 (ru) | Конструкции белка uspa2 и их применения | |
| JP2013518052A5 (enExample) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| JP2015529677A5 (enExample) |